EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Clinical and economic outcomes with rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea: retrospective analysis of US healthcare claims

Andrea Natale, Sanghamitra Mohanty, Cindy Chen, Yuan Zhao, Alicia K Campbell, Brahim Bookhart, Veronica Ashton

Journal of Interventional Cardiac Electrophysiology · 2024

DOI: 10.1007/s10840-024-01940-6 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Interventional Cardiac Electrophysiology, 2024. Verfasst von Andrea Natale und 6 weiteren Autor:innen. Beteiligte Einrichtung: Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA. Hauptthemen laut MEDLINE: Rivaroxaban, Warfarin, Atrial Fibrillation, Sleep Apnea, Obstructive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Scientific Affairs, LLC, a Johnson & Johnson Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atrial fibrillation (AF) and obstructive sleep apnea (OSA) are often comorbid and associated with increased risk of cardiovascular events such as stroke. We evaluated the effectiveness, safety, healthcare resource utilization, and costs of rivaroxaban versus warfarin in patients with nonvalvular AF (NVAF) and comorbid OSA.

Methods

We used the IQVIA PharMetrics ® Plus adjudicated claims database to evaluate patients with NVAF, OSA, and moderate-to-severe stroke risk who initiated rivaroxaban or warfarin between November 2011 and December 2022. We adjusted for potential confounders with propensity score overlap weighting. Primary endpoints were evaluated based on intent-to-treat (ITT) and on-treatment follow-up to compare stroke or systemic embolism risk, major bleeding risk, all-cause healthcare resource utilization (inpatient hospitalizations, emergency department visits, outpatient visits, and pharmacy fills), and costs (per patient per year [PPPY]) by treatment cohort.

Results

In total, 14,765 patients were included (9133 received rivaroxaban; 5632 received warfarin). Rivaroxaban significantly reduced stroke or systemic embolism versus warfarin by 26% (ITT—hazard ratio, 0.74 [95% CI 0.60–0.91]; P = 0.004) and 30% (on-treatment—hazard ratio, 0.70 [95% CI 0.55–0.89]; P = 0.004). Major bleeding was not significantly different between rivaroxaban and warfarin in either analysis. All-cause healthcare resource utilization was significantly reduced with rivaroxaban versus warfarin, leading to significantly reduced PPPY costs.

Conclusions

Among patients with NVAF and OSA, rivaroxaban was associated with a significant reduction in stroke or systemic embolism risk versus warfarin with no difference in major bleeding. Rivaroxaban significantly reduced healthcare resource utilization and costs compared with warfarin, providing support for the use of rivaroxaban in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanWarfarinAtrial FibrillationSleep Apnea, ObstructiveAnticoagulantsStrokeHumansFemaleMaleRetrospective StudiesUnited StatesAgedMiddle AgedFactor Xa InhibitorsTreatment Outcome

Stichwörter der Autor:innen

Atrial fibrillationHealthcare resource utilizationRivaroxabanSleep apnea

Substanzen

RivaroxabanWarfarinAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA.
  • Interventional Electrophysiology, Scripps Clinic, San Diego, CA, USA.
  • Metro Health Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Department of Biomedicine and Prevention, Division of Cardiology, University of Tor Vergata, Rome, Italy.
  • Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Titusville, NJ, USA.
  • Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Titusville, NJ, USA. vashton1@its.jnj.com.

Förderung

  • Janssen Scientific Affairs, LLC, a Johnson & Johnson Company

Zitieren

APA

Natale, A., Mohanty, S., Chen, C., Zhao, Y., Campbell, A. K., Bookhart, B., & Ashton, V. (2024). Clinical and economic outcomes with rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea: retrospective analysis of US healthcare claims. Journal of Interventional Cardiac Electrophysiology. https://doi.org/10.1007/s10840-024-01940-6

Vancouver

Natale A, Mohanty S, Chen C, Zhao Y, Campbell AK, Bookhart B, et al. Clinical and economic outcomes with rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea: retrospective analysis of US healthcare claims. Journal of Interventional Cardiac Electrophysiology. 2024. doi:10.1007/s10840-024-01940-6

BibTeX
@article{Natale2024,
  author = {Natale, Andrea and Mohanty, Sanghamitra and Chen, Cindy and Zhao, Yuan and Campbell, Alicia K and Bookhart, Brahim and Ashton, Veronica},
  title = {Clinical and economic outcomes with rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea: retrospective analysis of US healthcare claims},
  journal = {Journal of Interventional Cardiac Electrophysiology},
  year = {2024},
  doi = {10.1007/s10840-024-01940-6}
}
Kostenlos starten →